PMC10442482_01
Mean transprosthetic gradient immediately after TAVR, measured by TTE.
fcvm-10-1164432-g001.jpg
PMC10442482_01_fcvm-10-1164432-g001.jpg
F1
The mean transprosthetic gradient assessed by transthoracic echocardiography (TTE) was 5 mmHg (Figure 1), and the patient was discharged home on day 4 under dual antiplatelet therapy with aspirin and clopidogrel in the context of recent percutaneous coronary intervention (PCI).
Mean transprosthetic gradient at diagnosis of HIT, assessed by TTE.
fcvm-10-1164432-g002.jpg
PMC10442482_01_fcvm-10-1164432-g002.jpg
F2
By TTE, aortic valve thrombosis was suspected with significant elevation of the mean transprosthetic gradient at 28 mmHg and reduced leaflet motion of the right coronary cusp (Figure 2).
Cardiac tomography that shows a hypodense thickening of aortic cusps, confirming diagnosis of valve thrombosis, in sagittal (A) and transversal (B) views.
fcvm-10-1164432-g003.jpg
PMC10442482_01_fcvm-10-1164432-g003.jpg
F3
Cardiac tomography was performed that confirmed the diagnosis of bioprosthetic valve thrombosis with a hypodense thickening of the aortic cusps (Figure 3).
Mean transprosthetic gradient at discharge, after treatment with argatroban and initiation of Coumadin.
fcvm-10-1164432-g004.jpg
PMC10442482_01_fcvm-10-1164432-g004.jpg
F4
Cardiac echocardiography after 1 week of treatment with argatroban revealed a significant decrease in the mean transprosthetic gradient of 9 mmHg (Figure 4).